Chief Executive Officer, Entasis Therapeutics
Dr. Manos Perros is the Chief Executive Officer and co-founder of Entasis Therapeutics, a company applying cutting-edge science to develop a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Manos was central to the establishment of Entasis Therapeutics, which was formed with preclinical and clinical assets, proprietary technology and $40 million in seed funding from AstraZeneca in May 2015. He has since led the company’s development and raised an additional $50 million in a Series B financing.
Prior to founding Entasis, Manos was Vice President and Head of AstraZeneca’s Infection Research and Early Development organization for more than four years, and also served as Site Head for AstraZeneca’s Boston R&D research center in Waltham, MA. A chemist by training, Manos conducted his Ph.D. work in Belgium, France and Germany, and was an Associate in the Biophysics department at Yale from 1993-1995. Prior to joining AstraZeneca, Manos served as Director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as Vice-President and Chief Scientific Officer, Antivirals, at Pfizer. Manos has overseen a wide range of therapeutic areas, but his greatest contributions have been in the field of anti-infectives, where he is a distinguished and widely published scientist, having led research projects against HIV, Hepatitis C, influenza and fungal pathogens. Manos is a co-inventor of the first-in-class HIV treatment maraviroc (Celsentri/Selzentry) on which he worked from inception until the product’s launch. This medicine earned numerous accolades, including the 2008 Prix Galien USA. For his contributions to the discovery and development of maraviroc, Manos received the PhRMA Discoverer’s Award in 2010.